164 related articles for article (PubMed ID: 14634796)
21. Human CTL epitopes prostatic acid phosphatase-3 and six-transmembrane epithelial antigen of prostate-3 as candidates for prostate cancer immunotherapy.
Machlenkin A; Paz A; Bar Haim E; Goldberger O; Finkel E; Tirosh B; Volovitz I; Vadai E; Lugassy G; Cytron S; Lemonnier F; Tzehoval E; Eisenbach L
Cancer Res; 2005 Jul; 65(14):6435-42. PubMed ID: 16024648
[TBL] [Abstract][Full Text] [Related]
22. Prostate-specific antigen-derived epitopes capable of inducing cellular and humoral responses in HLA-A24+ prostate cancer patients.
Harada M; Kobayashi K; Matsueda S; Nakagawa M; Noguchi M; Itoh K
Prostate; 2003 Oct; 57(2):152-9. PubMed ID: 12949939
[TBL] [Abstract][Full Text] [Related]
23. Identification of HLA-A2- and A24-restricted T-cell epitopes derived from SOX6 expressed in glioma stem cells for immunotherapy.
Ueda R; Ohkusu-Tsukada K; Fusaki N; Soeda A; Kawase T; Kawakami Y; Toda M
Int J Cancer; 2010 Feb; 126(4):919-29. PubMed ID: 19728337
[TBL] [Abstract][Full Text] [Related]
24. Induction of human cytotoxic T lymphocytes specific for prostate-specific antigen.
Xue BH; Zhang Y; Sosman JA; Peace DJ
Prostate; 1997 Feb; 30(2):73-8. PubMed ID: 9051144
[TBL] [Abstract][Full Text] [Related]
25. A parathyroid-hormone-related-protein (PTH-rP)-specific cytotoxic T cell response induced by in vitro stimulation of tumour-infiltrating lymphocytes derived from prostate cancer metastases, with epitope peptide-loaded autologous dendritic cells and low-dose IL-2.
Correale P; Micheli L; Vecchio MT; Sabatino M; Petrioli R; Pozzessere D; Marsili S; Giorgi G; Lozzi L; Neri P; Francini G
Br J Cancer; 2001 Nov; 85(11):1722-30. PubMed ID: 11742494
[TBL] [Abstract][Full Text] [Related]
26. Identification of SART3-derived peptides capable of inducing HLA-A2-restricted and tumor-specific CTLs in cancer patients with different HLA-A2 subtypes.
Ito M; Shichijo S; Miyagi Y; Kobayashi T; Tsuda N; Yamada A; Saito N; Itoh K
Int J Cancer; 2000 Nov; 88(4):633-9. PubMed ID: 11058882
[TBL] [Abstract][Full Text] [Related]
27. Identification of HLA-A*0201-restricted cytotoxic T lymphocyte epitope from TRAG-3 antigen.
Zhu B; Chen Z; Cheng X; Lin Z; Guo J; Jia Z; Zou L; Wang Z; Hu Y; Wang D; Wu Y
Clin Cancer Res; 2003 May; 9(5):1850-7. PubMed ID: 12738743
[TBL] [Abstract][Full Text] [Related]
28. ABCE1, a member of ATP-binding cassette transporter gene, encodes peptides capable of inducing HLA-A2-restricted and tumor-reactive cytotoxic T lymphocytes in colon cancer patients.
Shichijo S; Ishihara Y; Azuma K; Komatsu N; Higashimoto N; Ito M; Nakamura T; Ueno T; Harada M; Itoh K
Oncol Rep; 2005 May; 13(5):907-13. PubMed ID: 15809757
[TBL] [Abstract][Full Text] [Related]
29. HLA-A2-restricted cytotoxic T lymphocyte epitopes from human hepsin as novel targets for prostate cancer immunotherapy.
Guo J; Li G; Tang J; Cao XB; Zhou QY; Fan ZJ; Zhu B; Pan XH
Scand J Immunol; 2013 Sep; 78(3):248-57. PubMed ID: 23721092
[TBL] [Abstract][Full Text] [Related]
30. Natural CD8+ T-cell responses against MHC class I epitopes of the HER-2/ neu oncoprotein in patients with epithelial tumors.
Sotiropoulou PA; Perez SA; Voelter V; Echner H; Missitzis I; Tsavaris NB; Papamichail M; Baxevanis CN
Cancer Immunol Immunother; 2003 Dec; 52(12):771-9. PubMed ID: 13680193
[TBL] [Abstract][Full Text] [Related]
31. Identification of SART3-derived peptides having the potential to induce cancer-reactive cytotoxic T lymphocytes from prostate cancer patients with HLA-A3 supertype alleles.
Minami T; Matsueda S; Takedatsu H; Tanaka M; Noguchi M; Uemura H; Itoh K; Harada M
Cancer Immunol Immunother; 2007 May; 56(5):689-98. PubMed ID: 16937115
[TBL] [Abstract][Full Text] [Related]
32. Dual antigen target-based immunotherapy for prostate cancer eliminates the growth of established tumors in mice.
Karan D; Dubey S; Van Veldhuizen P; Holzbeierlein JM; Tawfik O; Thrasher JB
Immunotherapy; 2011 Jun; 3(6):735-46. PubMed ID: 21668311
[TBL] [Abstract][Full Text] [Related]
33. In vitro generation of human cytotoxic T lymphocytes specific for peptides derived from prostate-specific antigen.
Correale P; Walmsley K; Nieroda C; Zaremba S; Zhu M; Schlom J; Tsang KY
J Natl Cancer Inst; 1997 Feb; 89(4):293-300. PubMed ID: 9048833
[TBL] [Abstract][Full Text] [Related]
34. Screening of HLA-A24-restricted epitope peptides from prostate-specific membrane antigen that induce specific antitumor cytotoxic T lymphocytes.
Horiguchi Y; Nukaya I; Okazawa K; Kawashima I; Fikes J; Sette A; Tachibana M; Takesako K; Murai M
Clin Cancer Res; 2002 Dec; 8(12):3885-92. PubMed ID: 12473604
[TBL] [Abstract][Full Text] [Related]
35. Phase I trial of patient-oriented vaccination in HLA-A2-positive patients with metastatic hormone-refractory prostate cancer.
Noguchi M; Itoh K; Suekane S; Yao A; Suetsugu N; Katagiri K; Yamada A; Yamana H; Noda S
Cancer Sci; 2004 Jan; 95(1):77-84. PubMed ID: 14720331
[TBL] [Abstract][Full Text] [Related]
36. Identification of an HLA-A*0201-restricted T-cell epitope derived from the prostate cancer-associated protein prostein.
Kiessling A; Stevanovic S; Füssel S; Weigle B; Rieger MA; Temme A; Rieber EP; Schmitz M
Br J Cancer; 2004 Mar; 90(5):1034-40. PubMed ID: 14997204
[TBL] [Abstract][Full Text] [Related]
37. Novel approach to the characterization of melanoma associated-peptide-specific CTL lines from Japanese metastatic melanoma patients.
Akiyama Y; Maruyama K; Tai S; Takikawa M; Ohshita C; Yamamoto A; Yamazaki N; Kiyohara Y; Yamaguchi K
Int J Oncol; 2008 Sep; 33(3):433-41. PubMed ID: 18695871
[TBL] [Abstract][Full Text] [Related]
38. Functional detection of epithelial cell adhesion molecule specific cytotoxic T lymphocytes in patients with lung cancer, colorectal cancer and in healthy donors.
Trojan A; Tun-Kyi A; Odermatt B; Nestle FO; Stahel RA
Lung Cancer; 2002 May; 36(2):151-8. PubMed ID: 11955649
[TBL] [Abstract][Full Text] [Related]
39. Peptides derived from human insulin-like growth factor-II mRNA binding protein 3 can induce human leukocyte antigen-A2-restricted cytotoxic T lymphocytes reactive to cancer cells.
Tomita Y; Harao M; Senju S; Imai K; Hirata S; Irie A; Inoue M; Hayashida Y; Yoshimoto K; Shiraishi K; Mori T; Nomori H; Kohrogi H; Nishimura Y
Cancer Sci; 2011 Jan; 102(1):71-8. PubMed ID: 21087352
[TBL] [Abstract][Full Text] [Related]
40. Variable expression on lung cancer cell lines of HLA-A2-binding MAGE-3 peptide recognized by cytotoxic T lymphocytes.
Takaki T; Hiraki A; Uenaka A; Gomi S; Itoh K; Udono H; Shibuya A; Tsuji T; Sekiguchi S; Nakayama E
Int J Oncol; 1998 May; 12(5):1103-9. PubMed ID: 9538136
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
